Pathophysiological and clinical aspects of narcolepsy: A disorder associated with hypocretin abnormalities

Somnologie

Volumn 4, Issue 3, 2000, Pages 111-116

  Hungs, M ^a   Mignot, E ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

CSF; Diagnosis; Genetics; Orexin; Receptor; Sleep; Therapy

Indexed keywords

OREXIN;

ARTICLE; CATAPLEXY; DISEASE ASSOCIATION; DOG; GENE MUTATION; HALLUCINATION; NARCOLEPSY; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; REM SLEEP; SOMNOLENCE;

EID: 0033780094     PISSN: 14329123     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11818-000-0002-4     Document Type: Article

References (40)

1. Diagnostic aspects of narcolepsy
2. Narcolepsy associated with lesions of the diencephalon
3. Validation of a cataplexy questionnaire in 983 sleep-disorders patients
4. Narcolepsy
5. The lateral hypothalamic area revisited: Neuroanatomy, body weight regulation, neuroendocrinoloy and metabolism
6. Breeding history of the Stanford colony of narcoleptic dogs
7. Narcolepsy in orexin knockout mice: Molecular genetics of sleep regulation
8. The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activity
9. HLA class II haplotype and sequence analysis support a role for DQ in narcolepsy
10. Mutation screening of hypocretin system in genes in human narcoleptics
11. CSF immune variable in patients with narcolepsy
12. In vivo and in vitro immune variables in patients with narcolepsy and HLA-DR2 matched controls
13. Synaptic interaction between hypocretin (orexin) and neuropeptide Y cells in the rodent and primate hypothalamus: A novel circuit implicated in metabolic and endocrine regulations
14. Hypocretin mutation screening in narcoleptic dogs
15. Effect of lateral cerebroventricular injection of the appetite-stimulating neuropeptide, orexin and neuropeptide Y, on the various behavioral activities of rats
16. HLA antigens in Japanese patients with narcolepsy. All the patients were DR2 positive
17. Genetic studies in the sleep disorder narcolepsy
18. Genetic markers in narcolepsy
19. Construction and characterization of an eightfold redundant dog genomic bacterial artificial chromosome library
20. Histaminergic descending inputs to the mesopontine tegmentum and their role in the control of cortical activation and wakefulness in the cat
21. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene
22. Functional neuroanatomy of human rapid-eye-movement sleep and dreaming
23. Perspectives in narcolepsy research and therapy
24. Genetic and familial aspects of narcolepsy
25. HLA DQB1*0602 is associated with Cataplexy in 509 narcoleptic patients
26. Heterozygosity at the canarc-1 locus can confer susceptibility for narcolepsy: Induction of cataplexy in heterozygous asymptomatic dogs after administration of a combination of drugs acting on monoaminergic and cholinergic systems
27. Narcolepsy and Immunity
28. Genetic linkage of autosoreal recessive canine narcolepsy with an immunglobulin heavy-chain switch-like segment
29. HLA and narcolepsy in a German population
30. Distribution of orexin neurons in the adult rat brain
31. Pharmacological aspects of human and canine narcolepsy
32. Hypocretin (orexin) deficiency in human narcolepsy
33. Neurons containing hypocretin (Orexin) project to multiple neuronal systems
34. HLA DR15 (DR2) and DQB1*0602 typing studies in 188 narcoleptic patients with cataplexy
35. HLA DR 2 association with excessive somnolence in narcolepsy does not generate to sleep apnea and is not accompanied by systemic autoimmune abnormalities
36. Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior
37. Increased body-mass index in patients with narcolepsy
38. 'Pressure to laugh': An unusual epileptic symptom associated with small hypothalamic hamartomas
39. Major histocompatibility class II molecules in the CNS: Increased microglial expression at the onset of narcolepsy in canine model
40. Orexin-induced food intake involves neuropeptide Y pathway